TNF Pharmaceuticals Files Q2 2025 10-Q
Ticker: QCLS · Form: 10-Q · Filed: Aug 19, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 10-Q |
| Filed Date | Aug 19, 2025 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, diagnostics, financials
TL;DR
TNF Pharma's Q2 2025 10-Q is in. Check financials.
AI Summary
TNF Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly known as MyMD Pharmaceuticals, Inc., is involved in in vitro & in vivo diagnostic substances. The filing details financial information and corporate actions for the second quarter of 2025.
Why It Matters
This filing provides investors with an update on TNF Pharmaceuticals' financial performance and operational status for the second quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — As a 10-Q filing, it contains detailed financial and operational information that requires careful analysis to assess the company's risk profile.
Key Numbers
- 20250630 — Reporting Period End Date (Indicates the end of the fiscal quarter for which the report is filed.)
- 20250819 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- MyMD Pharmaceuticals, Inc. (company) — Former name of TNF Pharmaceuticals, Inc.
- 20250630 (date) — End of the reporting period
- 20250819 (date) — Filing date
FAQ
What is the primary business of TNF Pharmaceuticals, Inc.?
TNF Pharmaceuticals, Inc. is involved in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' as indicated by its Standard Industrial Classification code.
What was TNF Pharmaceuticals, Inc. formerly known as?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc., with a name change date of 20210420.
For what period is this 10-Q filing?
This 10-Q filing is for the period ended June 30, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 19, 2025.
What are some of the convertible preferred stock series mentioned in relation to TNF Pharmaceuticals?
The filing mentions Series F Convertible Preferred Stock, Series F One Convertible Preferred Stock, Series G Convertible Preferred Stock, and Series D Convertible Preferred Stock in relation to TNF Pharmaceuticals.
Filing Stats: 4,726 words · 19 min read · ~16 pages · Grade level 18.6 · Accepted 2025-08-19 17:15:52
Key Financial Figures
- $0.001 — ed: Shares of Common Stock, par value $0.001 per share TNFA The Nasdaq Stock Mar
Filing Documents
- form10-q.htm (10-Q) — 1693KB
- ex3-1.htm (EX-3.1) — 16KB
- ex3-2.htm (EX-3.2) — 16KB
- ex10-1.htm (EX-10.1) — 37KB
- ex31-1.htm (EX-31.1) — 12KB
- ex31-2.htm (EX-31.2) — 12KB
- ex32-1.htm (EX-32.1) — 4KB
- ex32-2.htm (EX-32.2) — 7KB
- 0001641172-25-024859.txt ( ) — 7965KB
- tnfa-20250630.xsd (EX-101.SCH) — 55KB
- tnfa-20250630_cal.xml (EX-101.CAL) — 48KB
- tnfa-20250630_def.xml (EX-101.DEF) — 246KB
- tnfa-20250630_lab.xml (EX-101.LAB) — 468KB
- tnfa-20250630_pre.xml (EX-101.PRE) — 347KB
- form10-q_htm.xml (XML) — 1356KB
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION Item 1.
Financial Statements
Financial Statements 3 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 46 Item 4.
Controls and Procedures
Controls and Procedures 46
– OTHER INFORMATION
PART II – OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 47 Item 1A.
Risk Factors
Risk Factors 47 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3. Defaults Upon Senior Securities 47 Item 4. Mine Safety Disclosures 47 Item 5. Other Information 48 Item 6. Exhibits 48
Signatures
Signatures 49 2 PART I - Financial Information I tem 1. Financial Statements. TNF PHARMACEUTICALS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets June 30, 2025 and December 31, 2024 (unaudited) As of June 30, 2025 December 31, 2024 ASSETS Current Assets Cash $ 207,553 $ 173,154 Marketable Securities 3,605,508 8,345,082 Prepaid expenses 1,339,503 893,730 Total Current Assets 5,152,564 9,411,966 Non-Current Assets Lease Right-of-Use - 10,579 Goodwill 10,498,539 10,498,539 Investment in Oravax Medical 1,500,000 1,500,000 Total Non-Current Assets 11,998,539 12,009,118 Total Assets $ 17,151,103 $ 21,421,084 LIABILITIES Current Liabilities Trade and Other Payables $ 2,677,150 $ 2,902,104 Due to MyMD FL Shareholders 29,982 29,982 Lease Liability - 10,579 Dividends Payable 2,843,017 2,455,675 Derivative Liability - 1,303,000 Total Current Liabilities 5,550,149 6,701,340 Total Liabilities 5,550,149 6,701,340 Commitments and Contingencies - - Mezzanine Equity Series F Convertible Preferred Stock, par value $ 0.001 and a stated value of $ 1,100 per share, 15,000 shares designated as of June 30, 2025 and December 31, 2024, respectively, 4,382 and 4,211 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. Liquidation preference of $ 4,820,200 plus dividends at 10 % per annum of $ 2,406,294 as of June 30, 2025 5,130,667 4,930,004 Series F Convertible Preferred Stock – Discount - - Series F Convertible Preferred Stock – Derivative - - Convertible Preferred Stock – Derivative - - Series F-1 Convertible Preferred Stock, par value $ 0.001 and a stated value of $ 1,000 per share, 5,050 shares designated as of June 30, 2025 and December 31, 2024; 2,065 and 4,747 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. Liquidation preference of $ 2,065,000 plus dividends at 10 % per annum